Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com~Inclusion Criteria:~* Body Mass Index (BMI) of 18.0 to 33.0 kg/m\^2, inclusive. BMI = weight (kg)/(height \[m\])\^2~* Healthy based on medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG) at screening and check-in~Exclusion Criteria:~* Allergy to or hypersensitive to any of the drugs or nutritional supplement used in the study~* Prior history of Wernicke's Encephalopathy~* Thiamine deficiency~* Hypersensitivity to ondansetron~* Has any medical condition, medical history, or use of concomitant medication that is contraindicated in the applicable drug labeling~* Has history, deviated nasal septum, and/or obstructed airway, bleeding disorders, or other inabilities for insertion of nasogastric (NG) tube (Part 2 only)~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Treatment 1A (Type: EXPERIMENTAL): None
- Treatment 1B (Type: EXPERIMENTAL): None
- Treatment 2A (Type: EXPERIMENTAL): None
- Treatment 2B (Type: EXPERIMENTAL): None
- Treatment 2C (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).